Experimental verification of protective effect of hydrogen-rich water against cisplatin-induced nephrotoxicity in rats using dynamic contrast-enhanced CT
Kitamura A, Kobayashi S, Matsushita T, Fujinawa H, Murase K. · British Journal of Radiology. 2010;83(990):509.
Study at a glance
Preclinical
Thirty eight-week-old male Sprague-Dawley rats in a cisplatin-nephrotoxicity model.
Ad-libitum H₂-rich water beginning seven days before intraperitoneal cisplatin 3.6 mg/kg and continuing through day 7 after injection. · Dissolved H₂ concentration was 1.2 ± 0.1 mg/L in sealed 200 mL aluminium pouches. Daily water intake and ingested H₂ dose per kg were not reported.
H₂ water from seven days before cisplatin through the final day-7 assessment; CT on days 0, 2, 4 and 7.
Normalized renal-clearance measures were higher with H₂ water than with cisplatin plus standard water on days 2, 4 and 7; day-7 creatinine and tubular damage were lower. The treatment and healthy-control groups did not differ significantly for normalized whole-kidney clearance on days 2 and 7 or for serum creatinine. Whole-kidney clearance still fell significantly from baseline on day 4 in the H₂ group.
Small animal study, unequal group sizes, preventive exposure starting before cisplatin, ad-libitum intake not quantified, short seven-day follow-up, repeated iodinated-contrast imaging and no assessment of cisplatin antitumour efficacy in this experiment. I'rom Pharmaceutical provided the H₂ water and one author was affiliated with that company; no explicit funding or conflict declaration was identified, so absence is not inferred.
What kind of evidence is this?
Preclinical
Three-group controlled rat study with repeated dynamic contrast-enhanced CT
Kidney and urinary health
H₂-rich water
Information not yet classified
Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.
Methods
Thirty eight-week-old male Sprague-Dawley rats in a cisplatin-nephrotoxicity model.
30 rats: untreated control n=6, cisplatin with standard water n=12, and cisplatin with H₂-rich water n=12.
H₂ water from seven days before cisplatin through the final day-7 assessment; CT on days 0, 2, 4 and 7.
Ad-libitum H₂-rich water beginning seven days before intraperitoneal cisplatin 3.6 mg/kg and continuing through day 7 after injection.
H₂ dissolved in drinking water — H₂ only, not Brown's gas.
Dissolved H₂ concentration was 1.2 ± 0.1 mg/L in sealed 200 mL aluminium pouches. Daily water intake and ingested H₂ dose per kg were not reported.
Healthy rats with standard water and cisplatin-treated rats with standard water.
Outcomes and reported result
Renal contrast clearance per tissue volume and for the whole kidney, renal volume, serum creatinine, body weight and renal histopathology.
Normalized renal-clearance measures were higher with H₂ water than with cisplatin plus standard water on days 2, 4 and 7; day-7 creatinine and tubular damage were lower. The treatment and healthy-control groups did not differ significantly for normalized whole-kidney clearance on days 2 and 7 or for serum creatinine. Whole-kidney clearance still fell significantly from baseline on day 4 in the H₂ group.
The complete free PMC article was checked for all groups, water concentration and timing, functional and histological outcomes, null comparisons, safety comments, commercial material provision and available disclosures.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
Small animal study, unequal group sizes, preventive exposure starting before cisplatin, ad-libitum intake not quantified, short seven-day follow-up, repeated iodinated-contrast imaging and no assessment of cisplatin antitumour efficacy in this experiment. I'rom Pharmaceutical provided the H₂ water and one author was affiliated with that company; no explicit funding or conflict declaration was identified, so absence is not inferred.
Experimental cisplatin nephrotoxicity in rats; it does not establish kidney protection in patients receiving chemotherapy.
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
PMID: 20505032 · DOI: 10.1259/bjr/25604811
Free full article in PubMed Central.
Complete PMC article and PubMed metadata; full-text extraction checked 9 August 2026.
10 August 2026
Help people check the facts before they buy.
Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.